If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksK3 Business Technology Group Regulatory News (KBT)

  • There is currently no data for KBT

Placing

14 Jul 2011 12:20

RNS Number : 4095K
K3 Business Technology Group PLC
14 July 2011
 



14 July 2011

AIM: KBT

K3 BUSINESS TECHNOLOGY GROUP PLC

("K3" or "the Company")

 

Placing

 

K3, which provides and supports Enterprise Resource Planning software, hosting and managed services to the supply chain industry, is pleased to announce a placing of 2,564,408 new ordinary shares of 25p each ("New Ordinary Shares") at a price of 205p per share (the "New Placing") with new and existing institutional investors. The New Placing, which was oversubscribed, has raised a total of approximately £5.3 million (before expenses).

 

The placing price of 205p per share represents a discount of approximately 5.5% to the closing mid market share price on 13 July 2011, being the last practicable date prior to the issue of this announcement. The New Placing is, inter alia, conditional on admission of the New Ordinary Shares to trading on AIM ("Admission").

 

The proceeds of the New Placing will be used to support K3's strategy of seeking acquisitions to maximise the growth opportunities available. The Company has an established track record in successfully acquiring and integrating complementary businesses and the Board continues to identify targets which will add contracted, recurring income as well as those which will further develop the Company's product offering.

 

In addition to the New Placing, 1,200,000 existing ordinary shares on behalf of Laxnes B.V. ("Laxnes") and 63,993 existing ordinary shares on behalf of an employee of the Company have been placed with new and existing shareholders (the "Secondary Placing") at 205p per share. Following the Secondary Placing, Laxnes no longer has a disclosable interest in K3.

 

The 2,564,408 New Ordinary Shares represent approximately 9.0% of K3's enlarged issued share capital. Application has been made for the New Ordinary Shares to be admitted to trading on AIM and it is expected that admission will take place on 19 July 2011. The New Ordinary Shares will rank pari passu with the existing shares of the Company. Following this allotment the total issued share capital of the Company will increase to 28,472,163 ordinary shares.  Canaccord Genuity is acting as sole book runner in relation to both the New and Secondary Placings.

 

The Company is also pleased to announce it has further strengthened its cash resources for potential acquisitions, having agreed additional banking facilities with its existing bank, Barclays Bank PLC, to match the proceeds of the New Placing on a pound-for-pound basis.

 

Andy Makeham, Chief Executive of K3, commented, 

 

"We are delighted to have completed this placing with good support from both new and existing institutional shareholders. K3 has demonstrated its ability to deliver strong growth both organically and via acquisitions and we believe that the demand for shares in the placing reflects the exciting opportunities for further expansion.

 

With these funds in place, as well as the support of our bank, Barclays, K3 is well positioned to achieve its growth ambitions."

 

 For further information:

 

K3 Business Technology Group plc

Andy Makeham, Chief Executive

T: 0161 876 4498

David Bolton, Finance Director

Canaccord Genuity Limited (NOMAD)

Simon Bridges / Cameron Duncan

T: 020 7050 6500

Biddicks

Katie Tzouliadis / Sophie Lane

T: 020 3178 6378

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEBBGDRCBBBGBS
Date   Source Headline
1st Apr 20207:00 amRNSLoan Funding Secured and Update on Subsidiary
24th Mar 20207:00 amRNSDelay to Final Results
21st Feb 202011:28 amRNSHolding(s) in Company
18th Feb 20203:10 pmRNSDirector/PDMR Shareholding
17th Feb 202012:32 pmRNSBoard Appointment
6th Feb 20204:13 pmRNSBoard Changes
28th Oct 20196:15 pmRNSPDMR Announcement
24th Oct 20192:09 pmRNSDirector/PDMR Shareholding
22nd Oct 20192:00 pmRNSPrice Monitoring Extension
22nd Oct 20197:00 amRNSTrading update
12th Jul 20194:41 pmRNSPDMR Announcement
9th Jul 20197:00 amRNSInterim Results
18th Jun 20197:00 amRNSTrading Update
23rd May 20198:48 amRNSPDMR Announcement
22nd May 20192:05 pmRNSResult of AGM
19th Mar 20197:00 amRNSFinal Results
8th Feb 20192:42 pmRNSPDMR Dealings
22nd Jan 20191:06 pmRNSHolding(s) in Company
17th Dec 20187:00 amRNSTrading Update
29th Oct 20183:05 pmRNSHolding(s) in Company
20th Aug 20186:15 pmRNSHolding(s) in Company
9th Jul 20187:00 amRNSInterim Results
13th Jun 201810:44 amRNSHolding(s) in Company
11th Jun 20187:00 amRNSContracts Wins
7th Jun 20187:00 amRNSCapital Markets Afternoon & Notice of Results
30th May 201811:02 amRNSResult of AGM
30th May 20187:00 amRNSAGM Statement
6th Apr 20183:40 pmRNSHolding(s) in Company
5th Apr 20184:36 pmRNSPDMR Dealings
27th Mar 20187:00 amRNSFinal Results (17 months)
5th Mar 20183:48 pmRNSHolding(s) in Company
5th Jan 20189:50 amRNSHolding(s) in Company
27th Dec 20172:19 pmRNSDirector/PDMR Shareholding
12th Dec 20177:00 amRNSTrading Update
27th Sep 20177:00 amRNSSecond Interim Results
26th Sep 201711:52 amRNSHolding(s) in Company
18th Sep 201711:17 amRNSHolding(s) in Company
8th Aug 20173:55 pmRNSHolding(s) in Company
6th Jul 20175:25 pmRNSHolding(s) in Company
6th Jul 201710:48 amRNSPDMR Shareholding
6th Jul 20179:05 amRNSHolding(s) in Company
5th Jul 20171:17 pmRNSHolding(s) in Company
4th Jul 201711:41 amRNSReplacement:Result of General Meeting
4th Jul 201711:11 amRNSSIP Announcement
4th Jul 201711:06 amRNSResult of General Meeting
4th Jul 201710:36 amRNSHolding(s) in Company
4th Jul 20177:00 amRNSSigning of Facility Amendment Agreement
30th Jun 20177:00 amRNSResult of Open Offer
12th Jun 201712:58 pmRNSResults of Proposed Placing
12th Jun 20177:00 amRNSFundraising & Board Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.